Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2016-10-04 Capital/Financing Update
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
LANCEMENT DE L'INTRODUCTION EN BOURSE DU GROUPE PAROT SUR ALTERNEXT PARIS
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the launch of an Initial Public Offering (IPO) of Groupe PAROT on Alternext Paris. It details the capital increase, indicative price range, subscription period (October 4 to October 18, 2016), and the regulatory approval (visa n°16-459 from the AMF). This type of announcement, detailing fundraising activities, capital structure changes, and the process of issuing new shares to the public, directly corresponds to the 'Capital/Financing Update' category. It is not a full annual report (10-K), an interim report (IR), or just a notice of dividend (DIV). It is a specific announcement about raising capital via an IPO.
2016-10-04 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is clearly labeled as a "*Press release*" and announces Pharnext's continued support for the Hereditary Neuropathy Foundation (HNF) regarding Charcot-Marie-Tooth (CMT) disease awareness month. It contains company updates, quotes from executives, contact information, and background on CMT and Pharnext. This format is characteristic of an initial public announcement of news, rather than a comprehensive regulatory filing (like 10-K or IR) or a formal report itself. Since it is a press release announcing general corporate activity and partnership updates, it does not fit the specific categories like ER (Earnings Release), CAP (Financing), or DIRS (Insider Trading). The most appropriate general category for a non-standard, non-financial regulatory announcement that doesn't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for press releases disseminated via regulatory channels, or potentially a general Investor Relations document, but RNS is the best fit among the provided options for a general corporate news release.
2016-09-15 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a corporate action: Pharnext renewing its support for the Hereditary Neuropathy Foundation (HNF) in recognition of Charcot-Marie-Tooth (CMT) awareness month. It contains quotes from management and foundation leaders, contact information for investors and media, and boilerplate information about the disease and the company. This format is characteristic of a general corporate announcement or press release, which typically falls under the 'Regulatory Filings' (RNS) category if it doesn't fit a more specific financial disclosure like an Earnings Release (ER) or a specific event filing. Since it is not a full financial report (10-K, IR), a specific voting result (DVA), or a management discussion (MDA), RNS is the most appropriate general regulatory announcement category.
2016-09-15 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release announcing that data related to the company's drug candidate (PXT3003) will be presented at an upcoming scientific conference (CMTR Meeting). It details the poster numbers, session times, and the titles of the scientific presentations. This type of announcement, which publicizes participation in an industry or scientific event rather than releasing mandatory financial results (like 10-K, ER, IR) or official regulatory actions, fits best under the general category of Investor Relations or Regulatory Filings. Since it is a specific announcement about scientific data presentation, it is not a standard Earnings Release (ER), Interim Report (IR), or a formal Investor Presentation (IP) itself, but rather an announcement *about* presentations. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-standard corporate communications that don't fit the other defined categories (like DIV, CAP, MANG, etc.). It is not a Call Transcript (CT) or a formal Audit Report (AR).
2016-09-01 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release ('Communiqué de presse') announcing that data related to the drug PXT3003 will be presented at the 6th International Congress on Charcot-Marie-Tooth Disease. It details the poster sessions, dates, and times of the presentations. This type of announcement, which informs investors and the public about participation in a scientific conference or the presentation of research findings, is best classified as a general Investor Relations communication. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal proxy/voting document, and it is specifically about presenting data/research, it fits best under the general 'Regulatory Filings' (RNS) category as a broad investor communication, or potentially 'Investor Presentation' (IP) if it were the presentation itself. Given it is an announcement *about* presentations at a congress, RNS serves as the most appropriate general regulatory/investor announcement fallback, although it is highly specific. However, since it is an announcement about research data being presented, and not a formal financial filing, RNS is the best fit among the provided options for a non-standard announcement.
2016-09-01 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of two senior executives: René Goedkoop as Chief Medical Officer and François Chamoun as General Counsel. This type of announcement, detailing changes in the company's board or senior management team, directly corresponds to the definition of Board/Management Information (MANG). It is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), as it concerns specific personnel changes.
2016-07-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.